QNRX

Quoin Pharmaceuticals, Ltd.

NasdaqCMUSDEQUITY DELAYED

5.40

▲ 0.20 (3.90%)

MARKET · —

Price

Open

5.29

Prev close

5.20

Day high

5.88

Day low

5.02

Volume

71.85K

Market cap

—

P/E (TTM)

—

52W range

3.25 – 41.80

Trailing performance

Price return · vs SPY

Returnvs SPY

+9.43% +10.8%

+27.46% +23.7%

+14.85% +11.7%

-35.31% -46.4%

YTD

-61.40% -73.7%

-21.10% -41.1%

-96.99% -171.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

5.32

+1.60% from price

SMA 20

4.87

+14.46% from price

SMA 50

4.59

+21.43% from price

SMA 100

5.14

+5.19% from price

SMA 200

8.21

-32.15% from price

EMA 12

5.10

+5.96% from price

EMA 26

4.90

+10.36% from price

EMA 50

4.89

+10.43% from price

RSI (14)

60.5

Neutral

MACD (12,26,9)

0.20

Hist 0.02

ATR (14)

0.55

9.88% of price

Realised vol 30D

83.8%

Annualised

Bollinger upper

5.95

20, 2σ

Bollinger lower

3.78

20, 2σ

50 / 200 cross

Death

4.59 vs 8.21

Trend bias

Below 200

-32.15%

Risk profile

Daily returns · 1Y window

Beta vs SPY

-2.35

Less volatile than market

Correlation to SPY

-0.16

Largely independent

Realised vol 30D

83.8%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-85.4%

Peak to trough

Max drawdown 5Y

-100.0%

Peak to trough

ATR 14

0.55

9.88% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 5.40

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

QNRX · links out to the publisher

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results GlobeNewswire · 8d ago Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 GlobeNewswire · 15d ago Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome GlobeNewswire · 44d ago Quoin Pharmaceuticals Gets US Notice of Allowance for Netherton Syndrome Patent Application MT Newswires · 53d ago Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome GlobeNewswire · 53d ago Top Premarket Gainers MT Newswires · 59d ago Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval MT Newswires · 60d ago Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome GlobeNewswire · 60d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.